The U.S. Food and Drug Administration announced recently that it will not review Moderna’s mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and outside the industry concerned about the Trump administration’s approach to vaccine development and recommendations. Amna Nawaz discussed more with Michael Osterholm. #pbsnews #pbsnewshour #newshour #news #trumpadministration #mrna #vaccines #fda #moderna #hhs

Neustart in der mRNA-Forschung von Biontech-Gründern